Final height after long-term growth hormone treatment in Turner syndrome. European Study Group.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this randomized controlled trial publication.

To study final height after long-term growth hormone (GH) treatment in girls with Turner syndrome (TS).

Who Took Part

By PubMed's age tags, the people studied were children and teenagers, women only.

One hundred fifty three patients with TS, participating in five European trials, were included.

They started GH treatment in 1987-1989 at an age of 10 years or older.

How the Study Was Run

The design is described as randomized.

The participants were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

Mean age at start of treatment ranged between 11.7 and 14.6 years among countries and mean bone age between 9.4 and 11.8 years.

Fourteen girls were lost to follow-up, leaving 139 for analysis.

Sixty-one girls were still growing 10 mm/yr or more.

What Was Measured

PubMed files the paper under topics including Body Height, Europe, Growth Hormone, Linear Models, Logistic Models, Recombinant Proteins and Sensitivity and Specificity.

What This Means in Plain Language

The paper is a randomized study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 1995 (The Journal of pediatrics), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.